User login
Key clinical point: Scalp cooling therapy for chemotherapy-induced alopecia in patients with breast cancer is associated with 61% effectiveness, according to a meta-analysis.
Major finding: Scalp cooling therapy showed an effectiveness of 61% against hair loss. The region-specific efficacy was 65% in Europe and 53% in Asia.
Study details: Meta-analysis of 27 studies (3 randomized controlled trials, 12 cross-sectional, and 12 cohort studies) with 2,202 participants.
Disclosures: The study funding source was not identified. The authors declared no conflict of interests.
Source: Wang S et al. Support Care Cancer. 2021 Apr 13. doi: 10.1007/s00520-021-06188-8.
Key clinical point: Scalp cooling therapy for chemotherapy-induced alopecia in patients with breast cancer is associated with 61% effectiveness, according to a meta-analysis.
Major finding: Scalp cooling therapy showed an effectiveness of 61% against hair loss. The region-specific efficacy was 65% in Europe and 53% in Asia.
Study details: Meta-analysis of 27 studies (3 randomized controlled trials, 12 cross-sectional, and 12 cohort studies) with 2,202 participants.
Disclosures: The study funding source was not identified. The authors declared no conflict of interests.
Source: Wang S et al. Support Care Cancer. 2021 Apr 13. doi: 10.1007/s00520-021-06188-8.
Key clinical point: Scalp cooling therapy for chemotherapy-induced alopecia in patients with breast cancer is associated with 61% effectiveness, according to a meta-analysis.
Major finding: Scalp cooling therapy showed an effectiveness of 61% against hair loss. The region-specific efficacy was 65% in Europe and 53% in Asia.
Study details: Meta-analysis of 27 studies (3 randomized controlled trials, 12 cross-sectional, and 12 cohort studies) with 2,202 participants.
Disclosures: The study funding source was not identified. The authors declared no conflict of interests.
Source: Wang S et al. Support Care Cancer. 2021 Apr 13. doi: 10.1007/s00520-021-06188-8.